CVS Stock Surges on Positive Earnings, Analyst Upgrades

CVS Health Corporation (CVS) shares surged nearly 9.4% in pre-market trading on Thursday, February 13, 2025, following the company's release of fourth-quarter and full-year 2024 earnings results. The positive earnings report, coupled with analyst upgrades and price target increases, contributed to the stock's impressive performance.

CVS Health reported adjusted earnings per share (EPS) of $1.19 in the fourth quarter of 2024, surpassing the Zacks Consensus Estimate of $0.91 by 30.8%. Total revenue reached $97.7 billion, exceeding the $97.1 billion forecast and marking a year-over-year increase of 4.2%. The company's strong earnings results reflected growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments, partially offset by a decline in the Health Services segment.

Following the earnings release, several analysts upgraded their recommendations or raised their price targets for CVS Health stock. Leerink Partners' Michael Cherny upgraded the stock to an "outperform" rating and raised his price target to $75. David MacDonald of Truist Securities increased his price target to $76, while maintaining a "buy" recommendation. These analyst actions indicated that they believed the stock was undervalued and had potential for growth.

CVS Health's positive earnings results and analyst upgrades contributed to the stock's impressive performance on Thursday. The company's ability to exceed analyst expectations and provide positive guidance for 2025 boosted investor confidence in the company's prospects. The stock price movement reflects investors' positive reaction to the company's better-than-expected earnings and optimistic guidance for the coming year.




In conclusion, CVS Health's stock price surge on Thursday was driven by positive earnings results, analyst upgrades, and price target increases. The company's ability to exceed analyst expectations and provide positive guidance for 2025 contributed to the stock's impressive performance. Investors' positive reaction to the company's better-than-expected earnings and optimistic guidance for the coming year further boosted the stock's price. As CVS Health continues to address challenges in its Health Care Benefits segment and implement cost-cutting measures, investors will likely remain focused on the company's earnings performance and guidance.